Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-glutarato-N,N-diisopropyltryptamine
- Development stage
- Unknown
- Lead developer
- Terran Biosciences
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous, Oral
01
Overview
4-glutarato-N,N-diisopropyltryptamine (4-glutarato-DiPT) is a novel small molecule tryptamine prodrug being developed by CaaMTech for the treatment of postpartum depression and adjustment disorder. It is designed to be metabolically converted into its active form, 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT, also known as diprocin). 4-HO-DiPT is a synthetic structural analog of psilocin and serotonin that acts as a broad-spectrum serotonin receptor agonist, binding to ten of the fourteen known serotonin receptor subtypes, including the 5-HT2A receptor. This interaction is intended to produce psychedelic and neuroplastic effects to alleviate depressive symptoms. The compound is currently being evaluated in Phase 2 clinical trials.
- Other names
- 4-glutarate-N,N-diisopropyltryptamine4-glutarato-N,N-diisopropyltryptamine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)
Beyond the preview
Go deeper on 4-glutarato-N,N-diisopropyltryptamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-glutarato-N,N-diisopropyltryptamine.